Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by WalkOverTheStrton Aug 22, 2021 4:42pm
255 Views
Post# 33746498

RE:Can someone enlight me with transaminase mistery...

RE:Can someone enlight me with transaminase mistery...PH2 was for two weeks while the AME was 28 days. From last week's mgmt update LTE's are part of NSAIDs characteristics and mgmt believes it is from metabolites from naproxen not the hydrogen sulfide of Antibe's formula. So the premis a PH2 will test is that a lower does of naproxen with HS2 will be effective in pain relief (remember antibe's ph2 pain relief was at 2 weeks for other studies 12 weeks - see corp presenation for this on their website) and reduce ulcer risk. I'd try to listen to the 
Cancord webcast and I cannot find last week's shareholder meeting but that explained what I wrote above. 

https://wsw.com/webcast/canaccord60/ate.to/2745292

<< Previous
Bullboard Posts
Next >>